Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.51 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.51 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL669091 | 0.88 | ALDH1A1 (0.64) | ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL5761347 | 0.85 | ALDH1A1 (0.52) | ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL837798 | 0.85 | ALDH1A1 (0.56) | ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL567975 | 0.84 | ALDH1A1 (0.76) | ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13570729 | 0.84 | ALDH1A1 (0.50) | ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL31287794 | 0.84 | ALDH1A1 (0.76) | ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6964278 | 0.82 | ALDH1A1 (0.58) | ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13689282 | 0.81 | TAS1R3 (0.48) | ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL13687513 | 0.81 | TAS1R3 (0.48) | ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2 | |
| SCHEMBL29827163 | 0.81 | TAS1R3 (0.48) | ALDH1A1KDM4ETAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112574175-B | Quinoline compound, preparation method and application thereof | 南京长澳医药科技有限公司 | 2023-11-14 | — | — | CN | disclosed |
| WO-2021057190-A1 | QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海阳帆医药科技有限公司 | 2021-04-01 | — | — | WO | disclosed |
| WO-2021057190-A1 | QUINOLINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海阳帆医药科技有限公司 | 2021-04-01 | — | — | WO | disclosed |
| CN-112574175-A | Quinoline compound, preparation method and application thereof | 上海阳帆医药科技有限公司 | 2021-03-30 | — | — | CN | disclosed |
| WO-2011005295-A1 | MODULATORS OF THE SPHINGOSINE-1-PHOSPHATE (S1P) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | WO | disclosed |
| CN-101208299-A | Diarylsulfone sulfonamides and use therof | WYETH CORP (US) | 2008-06-25 | — | — | CN | disclosed |
| WO-2008060568-A2 | AMIDE-SUBSTITUTED ARYL PIPERIDINES | NEUROGEN CORPORATION (US) | 2008-05-22 | — | — | WO | disclosed |
| WO-2008061016-A1 | N-SUBSTITUTED PIPERIDINYL 4 -ARYLSULFONAMIDES AS MODULATORS OF THE SECRETED FRIZZLED RELATED PROTEIN- 1 | WYETH (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1879859-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | Wyeth a Corporation of the State of Delaware (US) | 2008-01-23 | — | — | EP | disclosed |
| US-20070032474-A1 | Use of a compound of formula 1 for making a pharmaceutical composition | BIONDI RICARDO M | 2007-02-08 | — | — | US | disclosed |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| CN-1286834-C | Benzothiazoles compound | HOFFMANN LA ROCHE CO LTD (CH) | 2006-11-29 | — | — | CN | disclosed |
| WO-2006124875-A2 | DIARYLSULFONE SULFONAMIDES AND USE THEROF | WYETH (US) | 2006-11-23 | — | — | WO | disclosed |
| EP-1456202-B1 | BENZOTHIAZOLES | HOFFMANN LA ROCHE (CH) | 2005-11-09 | — | — | EP | disclosed |
| CN-1602310-A | Benzothiazoles compound | HOFFMANN LA ROCHE (CH) | 2005-03-30 | — | — | CN | disclosed |
| EP-1456202-A1 | BENZOTHIAZOLES | F. Hoffman-la Roche AG (CH) | 2004-09-15 | — | — | EP | disclosed |
| US-6734179-B2 | SULFUR COMPOUNDS SUCH AS 4-FLUORO-N-(4-METHOXY-7-(TETRAHYDRO-PYRAN-4-YL)-BENZOTHIAZOL-2-YL) -BENZAMIDE, USED AS PREFERENTIAL ADENOSINE RECEPTOR LIGANDS FOR THE PROPHYLAXIS OF NEURODEGENERATIVE DISORDERS | HOFFMANN-LA ROCHE INC. | 2004-05-11 | — | — | US | disclosed |
| US-20030144288-A1 | Benzothiazoles | F. HOFFMAN-LA ROCHE AG A SWISS COMPANY (CH) | 2003-07-31 | — | — | US | disclosed |
| WO-2003053961-A1 | BENZOTHIAZOLES | F. HOFFMAN-LA ROCHE AG (CH) | 2003-07-03 | — | — | WO | disclosed |
| US-4690934-A | N-phenylsulfonylisonicotinamide derivatives and their use as fungicides or bactericides | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1987-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032474-A1 | Use of a compound of formula 1 for making a pharmaceutical composition | CYP7A1, UGT1A1, CYP2F1 | ALDH1A1 319/4885KDM4E 3975/4885TAS1R3 2569/4885 |
| US-20030144288-A1 | Benzothiazoles | ADORA2A, ADORA1, ADORA2B | ALDH1A1 89/4885KDM4E 3008/4885TAS1R3 240/4885 |
| US-20060276464-A1 | Diarylsulfone sulfonamides and use thereof | SFRP1, SOS1, FZD7 | ALDH1A1 1865/4885KDM4E 3044/4885TAS1R3 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.